Results 71 to 80 of about 62,432 (257)
Cyclic Guanosine 3′ ,5′-Monophosphate and Gallbladder Contraction
Cholecystokinin, acetylcholine, and oxymetazoline stimulated guanylyl cyclase activity in rabbit gallbladder. Cholecystokinin and acetylcholine also raised the intracellular levels of cyclic guanosine monophosphate in that tissue. The rise in intracellular cyclic guanosine monophosphate preceded and could mediate both the cholecystokinin- and ...
openaire +2 more sources
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao +4 more
wiley +1 more source
As second messengers, the cyclic purine nucleotides adenosine 3',5'-cyclic monophosphate (cAMP) and guanosine 3',5'-cyclic monophosphate (cGMP) play an essential role in intracellular signaling.
Daniel Reinecke +3 more
doaj +1 more source
Acidosis potentiates endothelium-dependent vasorelaxation and gap junction communication in the superior mesenteric artery. [PDF]
Extracellular pH is an important physiological determinant of vascular tone that is normally maintained within 7.35-7.45. Any change outside this range leads to severe pathological repercussions.
Mohanty, Ipsita +3 more
core +2 more sources
Cyclic guanosine monophosphate/adenosine monophosphate synthase (cGAS), innate immune responses, and viral hepatitis [PDF]
Abstract The type I interferon (IFN) response protects cells from viral infection by inducing hundreds of interferon-stimulated genes (ISGs), some of which encode direct antiviral effectors.
Eloi R. Verrier +8 more
openaire +2 more sources
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia +2 more
wiley +1 more source
Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo +7 more
wiley +1 more source
Mouse versus Rat: Profound Differences in Meiotic Regulation at the Level of the Isolated Oocyte [PDF]
Cumulus cell-enclosed oocytes (CEO), denuded oocytes (DO), or dissected follicles were obtained 44–48 hr after priming immature mice (20–23 days old) with 5 IU or immature rats (25–27 days old) with 12.5 IU of equine chorionic gonadotropin, and exposed ...
Biggers +61 more
core +2 more sources
Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
• Cilostazol is an oral PDE‐3 inhibitor that may have advantageous effects in heart failure with preserved ejection fraction (HFpEF). • Cilostazol significantly improved short‐term heart failure‐related health status scores (KCCQ‐12) and NT‐proBNP levels when compared to placebo.
Norman Aiad +9 more
wiley +1 more source
The Construction and Application of a New Screening Method for Phosphodiesterase Inhibitors
Phosphodiesterases (PDEs), a superfamily of enzymes that hydrolyze cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), are recognized as a therapeutic target for various diseases.
Chunhua Gao +8 more
doaj +1 more source

